Treatment Clinical Trials for Cervical Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for cervical cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-50 of 73

  • Phase 1 / 2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

    The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
    Location: 5 locations

  • Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer

    This is an open label, multi-center trial of tisotumab vedotin in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.
    Location: 3 locations

  • A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

    This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD / RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.
    Location: 4 locations

  • Study of REGN2810 in Adults With Cervical Cancer

    The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic cervical cancer treated with either REGN2810 (cemiplimab) or investigator's choice (IC) chemotherapy. The secondary objectives are: - To compare progression-free survival (PFS) of REGN2810 (cemiplimab) versus IC chemotherapy - To compare overall response rate (ORR) (partial response [PR] + complete response [CR]) of REGN2810 (cemiplimab) versus IC chemotherapy per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 - To compare the duration of response (DOR) of REGN2810 (cemiplimab) versus IC chemotherapy - To compare the safety profiles of REGN2810 (cemiplimab) versus IC chemotherapy by describing adverse events (AE) - To compare quality of life (QOL) for patients treated with REGN2810 (cemiplimab) versus IC chemotherapy using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
    Location: 3 locations

  • A Phase 1 / 2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

    This is a two-part Phase 1 / 2 dose escalation and dose expansion study of the GMCSF-encoding adenovirus, ONCOS-102, in combination with anti-programmed death ligand-1 (PDL1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian cancer or colorectal cancer.
    Location: 3 locations

  • A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

    The main objective of the dose-escalation part of the trial is to determine the safety and tolerability, and to determine the Maximum Tolerated Dose and / or the Recommended Phase 2 Dose (RP2D) of BI 754091 on the basis of patients with dose-limiting toxicities (DLTs) in patients with selected advanced solid malignancies. Safety and tolerability will be evaluated by monitoring the occurrence of adverse events (AEs), serious AEs (SAE), and laboratory parameter abnormalities, as well as changes to vital signs. Secondary objectives are the determination of the PK profile of BI 754091 after single and multiple doses of BI 754091, and the preliminary assessment of antitumour activity. In the dose-expansion part of the trial, the main objectives are to further assess the safety, efficacy, PK profile, and biomarkers of BI 754091 in tumours with specific tumour types and / or genetic mutations at the RP2D.
    Location: 3 locations

  • Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease

    This phase II trial studies how well stereotactic radiosurgery works in treating patients with cancer that has spread to 5 or fewer places in the body and involves 3 or fewer organs (oligometastatic disease). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
    Location: 3 locations

  • A Dose Escalation Study of PF‑06939999 in Participants With Advanced or Metastatic Solid Tumors.

    This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
    Location: 2 locations

  • A Study of XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors

    This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and / or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.
    Location: 4 locations

  • FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

    FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with advanced solid tumors.
    Location: 3 locations

  • A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254

    The main purpose of this clinical study is to determine the most appropriate dose of the study medication that can be safely given to subjects, and to look at how the study medication is changed and distributed by the body.
    Location: 2 locations

  • Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

    This is a Phase 1 / 2, open-label study of AGEN1884 in combination with AGEN2034 in subjects with locally advanced, recurrent and / or metastatic solid tumors including cervical cancer. AGEN2034 is a novel, fully human monoclonal immunoglobulin G4 (IgG4) antibody, designed to block program cell death-1 (PD-1). AGEN1884 is a novel, fully human monoclonal immunoglobulin G1 (IgG1) antibody, designed to block cytotoxic T-lymphocyte antigen-4 (CTLA-4).
    Location: 2 locations

  • Durvalumab, Tremelimumab, and Radiation Therapy in Treating Patients with Gynecologic Cancer That Is Metastatic or Cannot Be Removed by Surgery

    This phase I trial studies the side effects of durvalumab, tremelimumab, and radiation therapy in treating patients with gynecologic cancer that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab, tremelimumab, and radiation therapy may work better in treating patients with gynecologic cancer.
    Location: 2 locations

  • Internal Radiation Therapy with or without MRI Guidance in Treating Patients with Gynecologic Cancer

    This randomized clinical trial studies how well internal radiation therapy with or without magnetic resonance imaging (MRI) works in treating patients with gynecologic cancer. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Computer systems that allow doctors to create a 3-dimensional (3-D) picture of the tumor may help in planning radiation therapy and may result in more tumor cells being killed. Using a magnetic resonance (MR)-tracking device may improve the placement of the brachytherapy catheters.
    Location: 2 locations

  • Cyclophosphamide and IRX-2 in Treating Women with Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

    This randomized phase II trial studies how well cyclophosphamide and IRX-2 work in treating women with cervical squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neoplasia 3. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. IRX-2 may act as an immune booster to stimulate the immune system. Giving cyclophosphamide and IRX-2 may work better at treating cervical squamous intraepithelial neoplasia or squamous vulvar intraepithelial neoplasia.
    Location: 2 locations

  • A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

    This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). The study will consist of 2 phases: Dose Escalation Phase and Expansion Phase.
    Location: 2 locations

  • Phase 1 / 2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

    This trial is a Phase 1b / 2a trial designed to evaluate the safety and efficacy of adding oral AL3818 to standard platinum-based chemotherapy concurrently and continued as a maintenance therapy for up to 12 months.
    Location: 2 locations

  • Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies

    Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head and neck squamous cell carcinoma (HNSCC) as well as a variety of other tumor types. This study is designed primarily to assess the safety and tolerability of COTI-2 monotherapy or combination therapy in patients with advanced and recurrent malignancies to establish a recommended Phase 2 dose (RP2D) for future studies. Patients are currently being recruited for Part 3 of the study. Critical Outcome Technologies Inc. has been renamed to Cotinga Pharmaceuticals.
    Location: 2 locations

  • A Vaccine (TA-CIN) as Adjuvant Therapy in Treating Patients with HPV16 Related Stage IB1-IV Cervical Cancer

    This phase I trial studies the side effects of TA-CIN vaccine administered via arm or thigh in treating patients with HPV16 related stage IB1-IV cervical cancer. TA-CIN vaccine may teach the body’s immune system to recognize and get rid of the HPV16 virus. Giving TA-CIN after definitive treatment may kill any remaining tumor cells in patients with HPV16 related cervical cancer.
    Location: 2 locations

  • Vaccine Therapy in Treating Patients with HER2-Positive Solid Tumors

    This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with tumors that have a protein called human epidermal growth factor receptor 2 (HER2) on the surfaces of their cells. Vaccines made from a virus that has been modified to contain HER2 cells may help teach the immune system find and kill tumor cells.
    Location: 2 locations

  • A Study of Patients Receiving High-Dose Rate Brachytherapy

    Background: - One standard way of giving radiation is to combine external beam treatments with internal brachytherapy treatments, which involve short-range radiation therapy that gives a high dose of radiation directly to a cancer or to the area where cancer cells were removed. - Brachytherapy is done by placing hollow implant device(s) into the area to be treated and then moving a radiation source into each. The type of device depends on the type of cancer and the site to be treated. These devices can range from hollow applicators and needles to balloon-like equipment. Objectives: - To evaluate the quality of the brachytherapy procedure at the National Institutes of Health s Radiation Oncology Branch. Eligibility: - Patients with cancer who could potentially benefit from high-dose brachytherapy as part of their treatment. Design: - In conjunction with their existing treatment, patients will be treated with high-dose brachytherapy as determined appropriate for their particular type of cancer and cancer history. - Each treatment will take place in the Radiation Oncology Clinic. - If the patient does not have implant devices, the clinic staff will insert them and check their placement through a computed tomography (CT) scan. - The calculations to determine the appropriate brachytherapy dose will take a few hours; the brachytherapy treatment itself will take between 10 and 30 minutes. - The number of brachytherapy treatments will vary according to the individual needs and requirements of each type of cancer and each patient. - Patients will return to the Radiation Oncology Clinic for followup visits at 1, 3, 6, 9, and 12 months after the completion of radiation therapy. Followup evaluations will include a medical history and physical examination, assessment of any side effects of radiation therapy, and a repeat of any imaging (i.e., CT, MRI, X-ray) that was done at baseline to evaluate the tumor response.
    Location: 2 locations

  • A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer

    The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1 / PD-L1 bispecific antibody, in participants with advanced solid tumors.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

    A Phase 1 / 2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options in each indication and therefore will be patients for whom a clinical trial is appropriate.
    Location: M D Anderson Cancer Center, Houston, Texas

  • MRI-Guided Brachytherapy in Treating Participants with HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer

    This trial studies how well magnetic resonance imaging (MRI)-guided internal radiation therapy (brachytherapy) works in treating participants with human papillomavirus (HPV) associated stage IB2-IV cervical or stage II-IVA vaginal cancer. Using MRI guidance during brachytherapy applicator placement may improve treatment planning in participants with cervical or vaginal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Stereotactic Body Radiation Therapy and Atezolizumab in Treating Patients with Recurrent, Persistent, or Metastatic Cervical Cancer

    This phase II trial studies how well stereotactic body radiation therapy (SBRT) and atezolizumab works in treating patients with cervical cancer that has come back, persistent, or has spread to other places in the body. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SBRT and atezolizumab may work better in treating patients with cervical cancer.
    Location: Moffitt Cancer Center, Tampa, Florida